Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Deltec Asset Management LLC

Deltec Asset Management LLC lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,616,373 shares of the biopharmaceutical company’s stock after acquiring an additional 16,300 shares during the quarter. Ocular Therapeutix accounts for approximately 4.4% of Deltec Asset Management LLC’s portfolio, making the stock its 5th largest holding. Deltec Asset Management LLC owned about 1.66% of Ocular Therapeutix worth $22,344,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in OCUL. Squarepoint Ops LLC boosted its position in shares of Ocular Therapeutix by 275.3% during the 2nd quarter. Squarepoint Ops LLC now owns 64,911 shares of the biopharmaceutical company’s stock worth $444,000 after purchasing an additional 47,614 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Ocular Therapeutix by 61.5% during the second quarter. The Manufacturers Life Insurance Company now owns 116,964 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 44,524 shares in the last quarter. Algert Global LLC acquired a new position in Ocular Therapeutix during the second quarter worth about $69,000. Cetera Investment Advisers increased its holdings in Ocular Therapeutix by 1.8% in the second quarter. Cetera Investment Advisers now owns 739,044 shares of the biopharmaceutical company’s stock valued at $5,055,000 after buying an additional 13,054 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at approximately $393,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Price Performance

OCUL opened at $7.82 on Wednesday. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The company’s 50 day simple moving average is $8.61 and its 200 day simple moving average is $9.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of Ocular Therapeutix stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares of the company’s stock, valued at $2,424,221.59. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,368 shares of company stock worth $162,801 in the last quarter. 3.50% of the stock is owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.